110-306-002: A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)

Grants and Contracts Details

StatusActive
Effective start/end date4/19/22 → 4/19/26

Funding

  • AbbVie Incorporated: $2.00